Form 4: Cogent Biosciences Director Acquires Shares Via Stock Option Award

Director Karen Jean Ferrante acquired 2,462 shares of Cogent Biosciences through a stock option award in lieu of cash compensation.

Summary

• Karen Jean Ferrante, a director of Cogent Biosciences, acquired 2,462 shares of common stock through a stock option award on July 1, 2024.
• The stock option was granted in lieu of cash compensation for services as a director, according to the issuer's non-employee director compensation plan.
• The exercise price of the stock option is $8.94.
• The option is exercisable immediately and expires on July 1, 2034.
• The number of options granted was determined by dividing the cash compensation otherwise payable for the quarter by the Black-Scholes value of a single option as of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard compensation practice for a director, with no immediate positive or negative implications for the company's financial health.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

Directors often receive stock options as part of their compensation packages, aligning their interests with those of shareholders. This is a common practice in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across publicly traded companies, particularly in the biotech sector.
• The specific terms of the grant, such as the exercise price and vesting schedule, are typically determined by the company's compensation committee and are benchmarked against peer companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it demonstrates the director's increased alignment with the company's success.

Key Dates